About 5% of glioblastomas are estimated to represent secondary glioblastomas based on clinical and imaging data and between 6–13% of glioblastomas are estimated to represent secondary glioblastomas based on the mutational status of IDH [8,9]. This evidence concerns the gene IDH1 and glioblastoma.